Company

Remedy Plan Therapeutics

Remedy Plan Therapeutics develops drugs that target the NAMPT enzyme.

About

Remedy Plan is developing RPT1G, a NAMPT inhibitor in clinical trials for conditions including cancer, autoimmune disorders and metabolic diseases. The company is based in Gaithersburg, US, and raised USD 18.00 mn in May 2025 from Alexandria Venture Investments and Schooner Capital. The funding will support development of its pipeline for acute myeloid leukemia and myelodysplastic syndromes.

1Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in